Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol.
Background Hyperuricemia is a recognised risk factor for the development of nonalcoholic fatty liver disease (NAFLD). This study aims to investigate the therapeutic effect of resveratrol (RES) on the treatment of hyperuricemia-related NAFLD in rats and the underlying mechanisms. Methods NAFLD with hyperuricemia was induced in rats using high-yeast high-fat diet containing potassium oxonate. The impact of RES on liver pathology, and the expression of silent information regulator 1 (SIRT1), fork-head box class O-3a (FOXO3a), and nuclear factor kappa B subunit p65 (NF-κB p65) was analysed. Results RES significantly improved liver histology and reversed serum biochemical abnormalities. At the molecular level, RES improved insulin resistance (IR), inhibited hepatic steatosis, reduced oxidative stress and liver inflammation, and these effects were likely mediated through SIRT1-mediated FOXO3a phosphorylation and NF-κB P65 deacetylation. Conclusions Resveratrol is a promising agent for the treatment of hyperuricemia-related NAFLD through activating SIRT1 pathways.